Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
NCT06383520Phase 1Recruiting
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-XH06 in hepatocellular carcinoma (HCC). Primary endpoint: Visual and standardized uptake values assessment of lesions and biodistribution at 1 year. Started Sep 2023; status: recruiting.
02
Drugs
68Ga-XH06
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06383520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383520.